Microbiome specialist Seres announced a strategic reboot that will cut roughly 30% of its workforce and pause its lead program while refocusing resources on earlier‑stage, immunology‑focused research. The company said the move follows prolonged operational and financing challenges and aims to preserve runway for prioritized assets. Seres’ leadership framed the restructuring as necessary to right‑size the organization and advance a narrower set of science priorities; investors and partners will be watching for updates on program timelines and potential asset rationalizations. Source: company announcement and SEC filings.